{
    "root": "35bc723d-9108-57f9-e063-6394a90a5069",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "GLYCOPYRROLATE",
    "value": "20250518",
    "ingredients": [
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "GLYCOPYRROLATE",
            "code": "V92SO9WP2I"
        }
    ],
    "indications": "glycopyrrolate tablets indicated adults reduce symptoms peptic ulcer adjunct treatment peptic ulcer . limitations glycopyrrolate tablets indicated monotherapy treatment peptic ulcer effectiveness peptic ulcer healing established .",
    "contraindications": "important dosing information ( 2.1 ) glycopyrrolate tablets 2 mg recommended patients initiating treatment receiving maintenance treatment glycopyrrolate tablets 1 mg another 1 mg strength oral glycopyrrolate tablets . recommended ( 2.2 ) recommended initial glycopyrrolate tablets 1 mg 1 mg three times daily ( morning , early afternoon , bedtime ) . patients may require 2 mg bedtime assure overnight control symptoms . maintenance , 1 mg twice day frequently adequate . recommended glycopyrrolate tablets 2 mg adults 2 mg two three times daily equally spaced intervals . maximum recommended daily 8 mg. lowest effective glycopyrrolate control symptoms . patients titrated lower dose , switch glycopyrrolate tablets 2 mg glycopyrrolate tablets 1 mg another 1 mg oral tablet glycopyrrolate .",
    "warningsAndPrecautions": "glycopyrrolate tablets usp , 1 mg white off-white , round , beveled edge uncoated tablets , debossed ‘ ’ break line one side ‘ 08 ’ side . unit dose packages 100 ( 10 x 10 ) ndc 60687-458-01 store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . keep medication reach children . protection : blister torn broken .",
    "adverseReactions": "glycopyrrolate tablets contraindicated : patients risk anticholinergic toxicity due underlying medical condition , including : glaucoma [ ( 5.1 ) ] obstructive uropathies , including prostatic hypertrophy mechanical obstructive diseases gastrointestinal tract ( e.g . , pyloroduodenal stenosis , strictures ) [ ( 5.2 ) ] gastrointestinal motility disorders ( e.g . , achalasia , paralytic ileus , intestinal atony ) [ ( 5.3 ) ] bleeding gastrointestinal ulcer active inflammatory infectious colitis lead toxic megacolon history current toxic megacolon myasthenia gravis patients hypersensitivity glycopyrrolate inactive ingredients glycopyrrolate tablets [ ( 6 ) description ( 11 ) ] .",
    "indications_original": "Glycopyrrolate tablets are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.\n                  \n                     Limitations of Use\n                       Glycopyrrolate tablets are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.",
    "contraindications_original": "Important Dosing Information ( 2.1 ) Glycopyrrolate tablets 2 mg are not recommended for patients initiating treatment or receiving maintenance treatment with glycopyrrolate tablets 1 mg or another 1 mg dosage strength of oral glycopyrrolate tablets. Recommended Dosage ( 2.2 ) The recommended initial dosage of glycopyrrolate tablets 1 mg is 1 mg three times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms. For maintenance, a dosage of 1 mg twice a day is frequently adequate. The recommended dosage of glycopyrrolate tablets 2 mg for adults is 2 mg two or three times daily at equally spaced intervals. The maximum recommended daily dosage is 8 mg. Use the lowest effective dosage of glycopyrrolate to control symptoms. If patients can be titrated to a lower dose, switch from glycopyrrolate tablets 2 mg to glycopyrrolate tablets 1 mg or another 1 mg oral tablet of glycopyrrolate.",
    "warningsAndPrecautions_original": "Glycopyrrolate tablets USP, 1 mg are white to off-white, round, beveled edge uncoated tablets, debossed with ‘Y’ and break line on one side and ‘08’ on the other side.\n                  Unit dose packages of 100 (10 x 10) NDC 60687-458-01\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].\n                  Keep this and all medication out of the reach of children.\n                  \n                     FOR YOUR PROTECTION: Do not use if blister is torn or broken.",
    "adverseReactions_original": "Glycopyrrolate tablets are contraindicated in:\n                  \n                     Patients at risk for anticholinergic toxicity due to an underlying medical condition, including:\n  \n   \n                           Glaucoma\n    \n     [see\n                              \n                                 Warnings and Precautions (5.1)\n                              \n                              ]\n                           \n                           Obstructive uropathies, including prostatic hypertrophy\n                           Mechanical obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis, strictures)\n    \n     [see\n                              \n                                 Warnings and Precautions (5.2)\n                              \n                              ]\n                           \n                           Gastrointestinal motility disorders (e.g., achalasia, paralytic ileus, intestinal atony)\n    \n     [see\n                              \n                                 Warnings and Precautions (5.3)\n                              \n                              ]\n                           \n                           Bleeding gastrointestinal ulcer\n                           Active inflammatory or infectious colitis which can lead to toxic megacolon\n                           History of or current toxic megacolon\n                           Myasthenia gravis\n                        \n                     \n                     Patients with a hypersensitivity to glycopyrrolate or any of the inactive ingredients in glycopyrrolate tablets\n  \n   [see\n                        \n                           Adverse Reactions (6)\n                        \n                        and\n                        \n                           Description (11)\n                        \n                        ]."
}